Short Interest in Entero Therapeutics, Inc. (NASDAQ:GRDX) Declines By 44.6%

Entero Therapeutics, Inc. (NASDAQ:GRDX) was the target of a large decline in short interest in August. As of August 31st, there was short interest totaling 65,966 shares, a decline of 44.6% from the August 15th total of 118,986 shares. Approximately 0.9% of the company’s stock are short sold. Based on an average daily volume of 144,450 shares, the days-to-cover ratio is currently 0.5 days.

Entero Therapeutics Stock Performance

GRDX traded down $0.06 during mid-day trading on Tuesday, reaching $2.91. 49,365 shares of the stock were exchanged, compared to its average volume of 118,590. Entero Therapeutics has a 1 year low of $1.87 and a 1 year high of $6.93. The stock has a market capitalization of $20.73 million, a PE ratio of -1.54 and a beta of 1.87. The company has a 50 day moving average price of $3.47 and a two-hundred day moving average price of $3.46.

Analysts Set New Price Targets

Separately, Wall Street Zen lowered shares of Entero Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Saturday, August 29th.

Entero Therapeutics Company Profile

Entero Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company’s pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis.